No annual revenue total was found in Immunic, Inc.'s SEC filings.
Immunic, Inc. (IMUX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$86.0 million. As of Jun 30, 2026 it held $155.1 million in cash and investments and $567,000 in total debt.
Revenue
—
Net income (TTM)
$-111.57M
-9.6% vs year-ago TTM
Operating cash flow (TTM)
$-87.72M
+2.7% vs year-ago TTM
Free cash flow (TTM)
$-88.05M
+2.5% vs year-ago TTM
EPS (TTM)
$-0.66
+63.0% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
136.21M
+4.4% vs prior year
Net cash
$154.53M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMUX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, United States
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1280776
- Former names
- VITAL THERAPIES INC (until Apr 10, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M |
| Diluted EPS | -$0.62 | -$1.00 | -$2.11 | -$3.78 | -$3.93 |
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M |
| Stockholders' equity | -$6.7M | $18.4M | $28.9M | $113.7M | $127.1M |
| Cash and investments | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M |
| Total debt | $577,000 | $1.0M | $1.3M | $1.5M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Aug 11, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 14, 2026 |
All 832 Immunic, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.